Alzamend Neuro, Inc. (ALZN) Research

Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for neurodegenerative and psychiatric illnesses. Its development pipeline features two key candidates. AL001, currently in Phase II clinical trials, administers a proprietary blend of lithium, proline, and salicylate. This compound is designed to address a broad spectrum of conditions such as Alzheimer's, bipolar disorder, post-traumatic stress disorder (PTSD), major depressive disorder (MDD), and other neurodegenerative or psychiatric conditions. Also in its portfolio is AL002, which has successfully completed its preclinical phase. AL002 represents a cell-based therapeutic vaccine strategy, employing mutant-peptide sensitized cells to restore and enhance a patient's immune system in its fight against Alzheimer's disease. Incorporated in 2016, Alzamend Neuro, Inc. maintains its headquarters in Atlanta, Georgia.

Market snapshot

Symbol
ALZN
Price
$1.22
Day change
-2.40%
Market cap
$3.8M
P/E ratio
-0.66x
52-week range
0.84-3.6
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month

Peer companies

  • Acurx Pharmaceuticals, Inc. (ACXP)
  • Adial Pharmaceuticals, Inc. (ADIL)
  • Aprea Therapeutics, Inc. (APRE)
  • BioCardia, Inc. (BCDA)
  • Cardio Diagnostics Holdings, Inc. (CDIO)
  • Creative Medical Technology Holdings, Inc. (CELZ)
  • HCW Biologics Inc. (HCWB)
  • Kiora Pharmaceuticals, Inc. (KPRX)

Recent insider activity

  • AULT MILTON C III — P-Purchase (108388 shares) on 2026-04-14
  • AULT MILTON C III — S-Sale (1851 shares) on 2025-12-23
  • Horne William B. — S-Sale (3333 shares) on 2025-12-19
  • McGrath Lynne Fahey — S-Sale (30 shares) on 2025-10-23
  • AULT MILTON C III — C-Conversion (61743 shares) on 2025-10-08

Open Alzamend Neuro, Inc. (ALZN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.